Pharmaceuticals

Emgality Market 2026–2035 expanding with migraine prevention demand

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Emgality Market During 2026–2030?

The historical expansion can be primarily attributed to the high prevalence rates of migraine, the persistent unmet needs within chronic migraine care, the proven clinical efficacy of CGRP-targeting treatments, the increasing adoption of biologics by neurologists, and a heightened awareness in diagnostics.

The projected growth during the forecast period is fueled by an expanding population experiencing chronic migraines, the introduction of treatments for additional headache types, greater acceptance of biologic medications, enhanced patient compliance, and increasing expenditure on neurological healthcare.

Key trends anticipated in the forecast period involve the increasing use of CGRP inhibitors, a move towards therapies aimed at preventing migraines, a rising demand for sustained headache management, the broader application of biologic treatments in neurology, and patients’ preference for once-a-month injectable treatments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20054&type=smp

What Drivers Are Expected To Influence The Emgality Market During The Forecast Period?

The growing incidence of migraine is projected to stimulate the expansion of the emgality market. Migraine is a neurological disorder marked by severe, throbbing headaches, often accompanied by symptoms such as nausea, sensitivity to light and sound, and sometimes visual or sensory disturbances known as auras. Its prevalence is attributed to factors including escalating stress levels, lifestyle modifications, environmental triggers, and enhanced awareness and diagnosis of the condition. Emgality functions by blocking the calcitonin gene-related peptide (CGRP), which reduces the frequency and intensity of migraine attacks. This treatment delivers long-term relief, boosting quality of life and minimizing migraine-related disability for frequent sufferers. For example, in May 2023, Migraine Canada, a Canada-based organization supporting individuals with migraines, stated that migraines affect 12% of Canadians (4.5M) and over 1 billion globally, with a greater prevalence in women (30% lifetime) compared to men (8%) and children (10%). One in four households is impacted, with 1-2% suffering chronic migraines. Thus, the increasing prevalence of migraine will further drive the growth of the emgality market.

How Are The Various Segments Of The Emgality Market Categorized?

The emgality market covered in this report is segmented –

1) By Clinical Indication: Migraine Prevention, Cluster Headaches

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

What Trends Are Affecting The Expansion Of The Emgality Market?

A key trend in the Emgality market centers on a strategic partnership approach, designed to enhance technology integration and expand market reach. A strategic partnership is typically understood as a collaborative relationship between two or more organizations, combining their respective resources, expertise, and efforts to achieve mutual goals or objectives. For instance, in December 2023, Organon & Co., a US-based healthcare company with a focus on women’s health, broadened its existing partnership with Eli Lilly. This expansion aimed to widen access to the innovative migraine treatments, Emgality and RAYVOW, throughout Europe, by utilizing Organon’s specialized knowledge in central nervous system disorders and its established commercial capabilities. The collaboration specifically targets the significant impact of migraines on women and strengthens Organon’s portfolio in women’s health. Organon will be responsible for overseeing the distribution and promotion of these products, while Lilly will maintain their manufacturing and marketing authorization, ensuring the effective provision of these essential treatments.

Which Major Firms Influence Developments In The Emgality Market?

Major companies operating in the emgality market are Eli Lilly and Company

Read the full emgality market report here:

https://www.thebusinessresearchcompany.com/report/emgality-global-market-report

Which Region Is Forecast To Lead The Emgality Market In Terms Of Market Size?

North America was the largest region in the emgality market in 2025. The regions covered in the emgality market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Emgality Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20054&type=smp

Browse Through More Reports Similar to the Global Emgality Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Esg Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/esg-finance-global-market-report

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795